Computerized Anxiety Treatment for Suicide

Anxiety Clinical Trial

— CATS  

Official title:

Suicide Risk Prevention Among Patients With Anxiety Psychopathology

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01990131
• Other study ID #: RF02397
• Status: Completed
• Phase: N/A
• First received: November 15, 2013
• Last updated: August 8, 2016
• Start date: October 2013
• Est. completion date: July 2016

Study information

• Verified date: August 2016
• Source: Florida State University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the effectiveness and usability of multiple computer-based treatments for mood and anxiety relevant risk factors. The target of the treatment is related to cognitive stress, which has been shown to be associated with a variety of negative mental health outcomes such as Post-Traumatic Stress Disorder, suicidal ideation, and substance use disorders.

Description:

CATS is a newly developed computerized treatment targeting specific risk factors associated with anxiety symptoms and suicidal thoughts. Individuals will be asked to complete four appointments, where they will complete various self-report questionnaires as well as a newly developed computerized treatment targeting risk factors associated with anxiety.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: July 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meet diagnostic criteria for a primary Axis 1 anxiety disorder or meet diagnostic criteria for a unipolar mood disorder along with an Axis 1 anxiety disorder.

• Show evidence of current suicidal ideation (BSS above 6.

• Show elevated AS indicated by scoring at or above the community sample mean on the ASI-Cog (above 9.

Exclusion Criteria:

• No significant medical illness (e.g. sig cardiovascular disease, epilepsy, stroke).

• Current or past psychotic-spectrum disorders or uncontrolled bipolar disorder

• No current substance dependence

• Must be an English speaker.

• Must be 18 years or older.

• Must have normal or corrected vision

• Cannot begin treatment/therapy within 1 month of baseline.

• Cannot begin a new medication within 3 months of baseline.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders
• Suicide

Intervention

Other:
• Cognitive Anxiety Sensitivity Treatment

• Physical Health Education Training

Locations

Country	Name	City	State
United States	Anxiety and Behavioral Health Clinic	Tallahassee	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Florida State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anxiety Sensitivity Index-3 (ASI-3)	The ASI-3 is an 18-item self-report measure of anxiety sensitivity (AS). This scale was developed to provide a more stable measure of the three most widely recognized AS subfactors (cognitive, social and physical concerns) than the original ASI provides. Each subfactor is represented by six items. The measure has shown good psychometric properties.	Month 4 follow-up	No
Secondary	Beck Suicide Scale (BSS)	The BSS is a 21-item widely used self-report measure assessing a broad spectrum of behaviors and attitudes related to suicide risk, including suicidal ideation and past suicide attempts. It has demonstrated strong reliability and validity.	Month 4 follow-up	Yes